Abstract
Lymphocyte-activating gene-3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 is the third inhibitory receptor to be exploited in human anti-cancer immunotherapies. LAG-3 is considered a next-generation target in cancer immunotherapy, right next to PD-1 and CTLA-4.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
